Evidence map›Paper›PMID 40426553›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Virological and Pharmaceutical Properties of Clinically Relevant Phages.

Antonios-Periklis Panagiotopoulos, Antonia P Sagona, Deny Tsakri, Stefanos Ferous, Cleo Anastassopoulou, Athanasios Tsakris

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Microorganisms · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonios-Periklis PanagiotopoulosDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0003-2697-0654
Antonia P SagonaSchool of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.ORCID 0000-0002-0386-2322
Deny TsakriDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0003-1978-5864
Stefanos FerousDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0003-4670-5786
Cleo AnastassopoulouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-7666-9198
Athanasios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0656-4715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As antimicrobial resistance continues to undermine the efficacy of antibiotics, the global medical community is increasingly turning to alternative treatment modalities. Among these, phage therapy has re-emerged as a promising strategy for managing multidrug-resistant bacterial infections. Herein, we present and briefly discuss eight essential attributes of clinically relevant phages for therapy, which may be categorized broadly into virological and pharmacological characteristics. Virological attributes include a broad host range, a strictly lytic life cycle and the ability to manage the emergence of bacterial resistance to phages. Comprehensive genomic and proteomic characterization forms the foundation for selecting and engineering such candidates, ensuring both safety and predictability. From a pharmacological standpoint, phages should ideally show safety across relevant formulations and routes of administration, favorable pharmacokinetics, stability during storage and scalability in manufacturing. Advances in genomic analysis, artificial intelligence-driven phage selection and formulation technologies have further accelerated the translational potential of phage therapy. By systematically addressing each of these critical attributes, this work aims to inform the rational selection and development of therapeutic phages suitable for integration into the clinical practice.

Indexed as

antimicrobial resistancegenomic and proteomic characterizationlytic bacteriophagesphage therapypharmacokinetics

Identifiers

PMID40426553
PMCPMC12108485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.